Descubre RespirAP 2026, jornada clave en patología respiratoria con enfoque integral del paciente, formación práctica y oportunidades de investigación.
Analysis of eosinophilic bronchiectasis exploring airway inflammation, blood eosinophils, microbial associations and disease severity using LC-MS/MS techniques.
Whole-genome cfDNA profiling identifies molecular clusters and pathways associated with oxidative damage and airflow limitation in COPD patients.
Study exploring the association between eosinophils and circulating autoantibodies in COPD patients, considering airflow limitation and smoking status.
A 20 años de ECLIPSE, repasamos el estudio que transformó la comprensión de la EPOC, revelando su heterogeneidad, progresión y biomarcadores clave.
Lessons from the ANTES B+ study highlighting challenges in COPD clinical trials, recruitment difficulties, and implications for future study design.
Patients with COPD prioritise chronic symptoms and functional impact as key outcomes in COPD exacerbation treatment trials.
Early-stage lung immune infiltrate in idiopathic pulmonary fibrosis and its association with stable versus progressive disease in early IPF patients.
Review of the treatable traits approach in bronchiectasis, exploring phenotypes, endotypes, comorbidities, and its translation into clinical practice.
Participa en la Jornada RespirAP el 6 de mayo de 2026, un evento clave para impulsar un plan estratégico nacional en salud respiratoria. Formación, colaboración y acción.
